RecruitingNon-hematologic Cancer
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
Sponsor: Sequenom, Inc.
You may qualify if…
- ✓ Subject is 18 years of age or older;
- ✓ Subject is willing to provide written informed consent;
- ✓ Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;
- ✓ 1. residual tumor tissue available for testing by the Sponsor; or
- ✓ 2. genomic profiling results from an IVD or LDT assay performed on tumor biopsy tissue; or
- ✓ 3. an invasive procedure (biopsy, surgery) scheduled following the Baseline Visit from which residual tumor tissue can be available for testing by the Sponsor.
- ✓ Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.
You may not qualify if…
- ✕ Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.
- ✕ Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.
- ✕ Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).
- ✕ Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.
Where it's recruiting
Idaho
Boise
Source: ClinicalTrials.gov · NCT02586389 · last updated 2024-10-16